Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 (Cosentyx) Extension in Crohn's Disease
NCT01009281Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2009
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in Crohn's disease, sponsored by Novartis. Started Oct 2009; status: terminated.
02
Drugs
secukinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01009281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009281.